Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 71,837 shares, a growth of 14.3% from the February 12th total of 62,840 shares. Currently, 2.4% of the company’s shares are sold short. Based on an average daily volume of 18,567 shares, the days-to-cover ratio is currently 3.9 days. Based on an average daily volume of 18,567 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.4% of the company’s shares are sold short.

Analysts Set New Price Targets

XCUR has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. Wall Street Zen raised shares of Exicure to a “hold” rating in a research report on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Exicure has a consensus rating of “Sell”.

Exicure Stock Performance

Exicure stock opened at $4.54 on Wednesday. The company has a market cap of $28.92 million, a P/E ratio of -1.23 and a beta of 4.13. Exicure has a one year low of $3.10 and a one year high of $15.91. The business has a fifty day moving average of $4.58 and a two-hundred day moving average of $4.69.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.